Stanimir Georgiev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stanimir Georgiev has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Peter Ewert
Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum München, Technische Universität München, 80636 München, Germany
18 shared publications Peter Ewert
Department of Congenital Heart Defects and Pediatric Cardiology, German Heart Center, TUM University Hospital, Technical University of Munich, Munich, Germany
15 shared publications- Alfred Hager
Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München , Munich
14 shared publications Andreas Eicken
TUM University Hospital, Technical University of Munich
14 shared publications- Masamichi Ono
Department of Congenital and Pediatric Heart Surgery, TUM University Hospital, German Heart Center, Munich, Germany; Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig- Maximilians-Universität München, Munich, Germany; Europäisches Kinderherzzentrum München , Munich 80636
11 shared publications - Daniel Tanase
Clinic for Congenital Heart Disease and Pediatric Cardiology (H.L., V.S., C.M., D.T., A.E., P.E., S.G.), German Heart Centre Munich
10 shared publications
Latest Publications
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Percutaneous Pacemaker Lead Implantation in Patients With Univentricular Circulation and Selected Patients With Biventricular Circulation: Intracavitary and Intramyocardial Approaches
Background: Epicardial pacemaker lead implantation in patients with univentricular circulation following total cavopulmonary connection with an extracardiac conduit and without fenestration necessitates median sternotomy. Transvenous access, although possible and previously described, may be technically challenging in this population and carries an increased risk of lead‐related thrombosis within the subsystemic atrium or ventricle. Surgical implantation usually requires mechanical ventilation and is associated with procedural morbidity. A percutaneous approach represents a minimally invasive treatment option that can be applied in this subgroup and in selected patients with biventricular circulation. We report on 9 patients in whom a pacemaker lead was implanted percutaneously with the use of a puncture sheath. Methods: Patients with pacemaker indications and anatomic constraints precluding conventional transvenous access underwent computed tomographic imaging for procedural planning. Eight patients had single‐ventricle physiology, and 1 patient had biventricular circulation with severely impaired ventricular function. Results: Percutaneous pacemaker lead implantation was successful in all 9 patients. The median age was 11.2 (range, 6.0–43.8) years, and median weight was 22.0 (range, 19.9–68.5) kg. In 6 patients, the puncture was performed via the subxyphoidal approach, in 1 patient via the transthoracic approach, and in 2 patients, venous access was used (subclavian vein, n=1; internal jugular vein, n=1). The median follow‐up time was 26.5 (range, 0.1–64.8) months. Only 1 patient required reintervention for lead dysfunction after 26 months; in all others, lead thresholds remained stable. Conclusions: Percutaneous intramyocardial and intracavitary pacemaker lead implantation is feasible and may obviate the need for surgery. However, in selected cases, identifying a suitable landing zone may be challenging due to prior surgical interventions, scarring, or fibrosis.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Percutaneous Pacemaker Lead Implantation in Patients With Univentricular Circulation and Selected Patients With Biventricular Circulation: Intracavitary and Intramyocardial Approaches
Background: Epicardial pacemaker lead implantation in patients with univentricular circulation following total cavopulmonary connection with an extracardiac conduit and without fenestration necessitates median sternotomy. Transvenous access, although possible and previously described, may be technically challenging in this population and carries an increased risk of lead‐related thrombosis within the subsystemic atrium or ventricle. Surgical implantation usually requires mechanical ventilation and is associated with procedural morbidity. A percutaneous approach represents a minimally invasive treatment option that can be applied in this subgroup and in selected patients with biventricular circulation. We report on 9 patients in whom a pacemaker lead was implanted percutaneously with the use of a puncture sheath. Methods: Patients with pacemaker indications and anatomic constraints precluding conventional transvenous access underwent computed tomographic imaging for procedural planning. Eight patients had single‐ventricle physiology, and 1 patient had biventricular circulation with severely impaired ventricular function. Results: Percutaneous pacemaker lead implantation was successful in all 9 patients. The median age was 11.2 (range, 6.0–43.8) years, and median weight was 22.0 (range, 19.9–68.5) kg. In 6 patients, the puncture was performed via the subxyphoidal approach, in 1 patient via the transthoracic approach, and in 2 patients, venous access was used (subclavian vein, n=1; internal jugular vein, n=1). The median follow‐up time was 26.5 (range, 0.1–64.8) months. Only 1 patient required reintervention for lead dysfunction after 26 months; in all others, lead thresholds remained stable. Conclusions: Percutaneous intramyocardial and intracavitary pacemaker lead implantation is feasible and may obviate the need for surgery. However, in selected cases, identifying a suitable landing zone may be challenging due to prior surgical interventions, scarring, or fibrosis.
- 18 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9) , e016616
Prospective Midterm Outcomes of the PULSTA Self-Expandable Transcatheter Pulmonary Valve: The PULSTA CE Approval Study
BACKGROUND: Patients with congenital or acquired right ventricular outflow tract dysfunction frequently require pulmonary valve replacement and are exposed to repeated surgical interventions due to prosthetic valve degeneration. The PULSTA self-expanding transcatheter pulmonary valve was designed to address a broad spectrum of native and surgically repaired right ventricular outflow tract anatomies. This study reports the midterm safety, hemodynamic performance, and durability outcomes of the prospective, multinational PULSTA CE approval trial (PULSTA Carpentier Edwards). METHODS: This premarket, multicenter, nonrandomized study enrolled 58 patients across 11 centers in 6 countries. Successful PULSTA implantation was achieved in 57 patients (98.3%), including 4 valve-in-valve procedures. Patients were followed for a median duration of 4.1 years. Primary end points included procedural or device-related serious adverse events, hemodynamic improvement, and sustained valve function. RESULTS: At 6 months, cardiac magnetic resonance imaging demonstrated significant reverse right ventricular remodeling, with marked reductions in right ventricular end-diastolic volume index, end-systolic volume index, and pulmonary regurgitation fraction (all P <0.001). Valve performance remained stable throughout follow-up, with 93.8% of patients exhibiting mild or less pulmonary regurgitation at 4.1 years. Freedom from reintervention was 98.2% at 5 years. One patient required a PULSTA-in-PULSTA implantation due to paravalvular leakage, and one case of infective endocarditis was successfully managed with antibiotic therapy. No stent fractures or structural valve deterioration were observed. CONCLUSIONS: The PULSTA transcatheter pulmonary valve demonstrated high procedural success, durable valve function, and sustained hemodynamic benefits. Its adaptability to diverse right ventricular outflow tract anatomies and favorable safety profile supports its role as an effective therapeutic option for patients with right ventricular outflow tract dysfunction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03983512.
- 18 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9) , e016616
Prospective Midterm Outcomes of the PULSTA Self-Expandable Transcatheter Pulmonary Valve: The PULSTA CE Approval Study
BACKGROUND: Patients with congenital or acquired right ventricular outflow tract dysfunction frequently require pulmonary valve replacement and are exposed to repeated surgical interventions due to prosthetic valve degeneration. The PULSTA self-expanding transcatheter pulmonary valve was designed to address a broad spectrum of native and surgically repaired right ventricular outflow tract anatomies. This study reports the midterm safety, hemodynamic performance, and durability outcomes of the prospective, multinational PULSTA CE approval trial (PULSTA Carpentier Edwards). METHODS: This premarket, multicenter, nonrandomized study enrolled 58 patients across 11 centers in 6 countries. Successful PULSTA implantation was achieved in 57 patients (98.3%), including 4 valve-in-valve procedures. Patients were followed for a median duration of 4.1 years. Primary end points included procedural or device-related serious adverse events, hemodynamic improvement, and sustained valve function. RESULTS: At 6 months, cardiac magnetic resonance imaging demonstrated significant reverse right ventricular remodeling, with marked reductions in right ventricular end-diastolic volume index, end-systolic volume index, and pulmonary regurgitation fraction (all P <0.001). Valve performance remained stable throughout follow-up, with 93.8% of patients exhibiting mild or less pulmonary regurgitation at 4.1 years. Freedom from reintervention was 98.2% at 5 years. One patient required a PULSTA-in-PULSTA implantation due to paravalvular leakage, and one case of infective endocarditis was successfully managed with antibiotic therapy. No stent fractures or structural valve deterioration were observed. CONCLUSIONS: The PULSTA transcatheter pulmonary valve demonstrated high procedural success, durable valve function, and sustained hemodynamic benefits. Its adaptability to diverse right ventricular outflow tract anatomies and favorable safety profile supports its role as an effective therapeutic option for patients with right ventricular outflow tract dysfunction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03983512.
- Open Access
- 12 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2930
Cross-Sectional Area Changes in the Total Cavopulmonary Connection Pathway and Its Impact on Liver Fibrosis
Background/Objectives: A known disadvantage of extracardiac Fontan is the absence of growth potential and potential late flow stagnation compared to lateral tunnel Fontan. This study investigates the differences in changes in the cross-sectional area and impact on liver fibrosis. Methods: The anteroposterior and lateral diameters of the Fontan pathways were measured using angiograms. Cross-sectional area and the indexed cross-sectional area were calculated, and their relation to Fibrosis-4 index was analyzed. Results: A total of 334 angiograms of 224 patients (212 extracardiac and 12 lateral tunnel Fontan) were evaluated. The median age at Fontan was 2.2 (Interquartile Range: 1.8–2.9) years. The median period from Fontan to angiogram was 3.3 (0.04–10.8) years. Cross-sectional areas remained unchanged in extracardiac Fontan patients and increased in lateral tunnel Fontan patients. The indexed cross-sectional areas in extracardiac Fontan patients decreased over time. The smallest indexed-cross-sectional areas were 200 mm2/m2 in extracardiac Fontan patients at 10 years postoperatively, whereas indexed cross-sectional areas in lateral tunnel Fontan patients were larger and more variable. Fibrosis-4 index increased time-dependently in both groups. Indexed cross-sectional area at the smallest level 2/m2 was identified as a risk factor for liver fibrosis. Conclusions: The Fontan pathway expanded in patients after lateral tunnel Fontan, whereas indexed cross-sectional area decreased over time after extracardiac Fontan. Importantly, in patients after extracardiac Fontan, narrowing of the Fontan pathway might be one of the risk factors for progression of liver fibrosis.
- 12 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2930
Open AccessCross-Sectional Area Changes in the Total Cavopulmonary Connection Pathway and Its Impact on Liver Fibrosis
Background/Objectives: A known disadvantage of extracardiac Fontan is the absence of growth potential and potential late flow stagnation compared to lateral tunnel Fontan. This study investigates the differences in changes in the cross-sectional area and impact on liver fibrosis. Methods: The anteroposterior and lateral diameters of the Fontan pathways were measured using angiograms. Cross-sectional area and the indexed cross-sectional area were calculated, and their relation to Fibrosis-4 index was analyzed. Results: A total of 334 angiograms of 224 patients (212 extracardiac and 12 lateral tunnel Fontan) were evaluated. The median age at Fontan was 2.2 (Interquartile Range: 1.8–2.9) years. The median period from Fontan to angiogram was 3.3 (0.04–10.8) years. Cross-sectional areas remained unchanged in extracardiac Fontan patients and increased in lateral tunnel Fontan patients. The indexed cross-sectional areas in extracardiac Fontan patients decreased over time. The smallest indexed-cross-sectional areas were 200 mm2/m2 in extracardiac Fontan patients at 10 years postoperatively, whereas indexed cross-sectional areas in lateral tunnel Fontan patients were larger and more variable. Fibrosis-4 index increased time-dependently in both groups. Indexed cross-sectional area at the smallest level 2/m2 was identified as a risk factor for liver fibrosis. Conclusions: The Fontan pathway expanded in patients after lateral tunnel Fontan, whereas indexed cross-sectional area decreased over time after extracardiac Fontan. Importantly, in patients after extracardiac Fontan, narrowing of the Fontan pathway might be one of the risk factors for progression of liver fibrosis.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (2) , e013235
Real-Time Biventricular Pressure-Volume Loops During Percutaneous Pulmonary Valve Implantation in Patients With RVOT Dysfunction
BACKGROUND: In patients with right ventricular (RV) outflow tract stenosis and pulmonary regurgitation (PR), percutaneous pulmonary valve implantation (PPVI) aims to preserve RV and left ventricular (LV) integrity and function. Our study aimed to assess acute changes in biventricular intrinsic myocardial function occurring with PPVI. METHODS: Twenty patients with RV outflow tract dysfunction (mean±1 SD; age, 23.0±10.9 years; mean peak echocardiographic RV outflow tract gradient, 64±25 mm Hg) underwent PPVI with biventricular assessment of pressure-volume loops using the conductance catheter technique during the same cardiac catheterization. Load-independent parameters of ventricular contractility (ventricular elastance) and ventricular compliance function, as well as pulmonary/systemic arterial elastance and ventriculoarterial coupling, were assessed before and directly after PPVI. Cardiac magnetic resonance for quantification of biventricular volumes, function, and PR was also performed. RESULTS: After PPVI, both RV ventricular elastance (median [interquartile range], 0.26 [0.16–0.83] to 0.19 [0.13–0.42] mm Hg/mL per m 2 ; P =0.029) and pulmonary systemic arterial elastance (0.32±0.20 to 0.25±0.19 mm Hg/mL per m 2 ; P P =0.76) did not change statistically significant. LV ventricular elastance (1.31±0.93 to 1.23±0.72 mm Hg/mL per m 2 ; P =0.68) and left ventriculoarterial coupling (0.75 [0.51–1.23] to 0.82 [0.53–1.10]; P =0.98) were not affected by PPVI although systemic arterial elastance increased significantly (0.83±0.26 to 0.90±0.34 mm Hg/mL per m 2 ; P =0.032). Both RV ( P =0.37) and LV ( P =0.20) compliance showed no significant change after PPVI. Patients with relevant PR (≥25%; n=10) had lower RV ventricular elastance ( P =0.043) before and higher LV compliance ( P =0.010) after PPVI compared with patients with minor PR (<25%; n=10), whereas ventriculoarterial coupling was similar between the 2 groups. CONCLUSIONS: Acute reduction of RV overload by PPVI is accompanied by an instantaneous decline in RV contractility with persistent and inefficient ventriculoarterial coupling. The LV adequately adapts to an increase in pre- and post-load with nonsignificant changes in LV intrinsic function and ventriculoarterial coupling. The relevance of these response patterns on long-term biventricular remodeling requires further investigation.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (2) , e013235
Real-Time Biventricular Pressure-Volume Loops During Percutaneous Pulmonary Valve Implantation in Patients With RVOT Dysfunction
BACKGROUND: In patients with right ventricular (RV) outflow tract stenosis and pulmonary regurgitation (PR), percutaneous pulmonary valve implantation (PPVI) aims to preserve RV and left ventricular (LV) integrity and function. Our study aimed to assess acute changes in biventricular intrinsic myocardial function occurring with PPVI. METHODS: Twenty patients with RV outflow tract dysfunction (mean±1 SD; age, 23.0±10.9 years; mean peak echocardiographic RV outflow tract gradient, 64±25 mm Hg) underwent PPVI with biventricular assessment of pressure-volume loops using the conductance catheter technique during the same cardiac catheterization. Load-independent parameters of ventricular contractility (ventricular elastance) and ventricular compliance function, as well as pulmonary/systemic arterial elastance and ventriculoarterial coupling, were assessed before and directly after PPVI. Cardiac magnetic resonance for quantification of biventricular volumes, function, and PR was also performed. RESULTS: After PPVI, both RV ventricular elastance (median [interquartile range], 0.26 [0.16–0.83] to 0.19 [0.13–0.42] mm Hg/mL per m 2 ; P =0.029) and pulmonary systemic arterial elastance (0.32±0.20 to 0.25±0.19 mm Hg/mL per m 2 ; P P =0.76) did not change statistically significant. LV ventricular elastance (1.31±0.93 to 1.23±0.72 mm Hg/mL per m 2 ; P =0.68) and left ventriculoarterial coupling (0.75 [0.51–1.23] to 0.82 [0.53–1.10]; P =0.98) were not affected by PPVI although systemic arterial elastance increased significantly (0.83±0.26 to 0.90±0.34 mm Hg/mL per m 2 ; P =0.032). Both RV ( P =0.37) and LV ( P =0.20) compliance showed no significant change after PPVI. Patients with relevant PR (≥25%; n=10) had lower RV ventricular elastance ( P =0.043) before and higher LV compliance ( P =0.010) after PPVI compared with patients with minor PR (<25%; n=10), whereas ventriculoarterial coupling was similar between the 2 groups. CONCLUSIONS: Acute reduction of RV overload by PPVI is accompanied by an instantaneous decline in RV contractility with persistent and inefficient ventriculoarterial coupling. The LV adequately adapts to an increase in pre- and post-load with nonsignificant changes in LV intrinsic function and ventriculoarterial coupling. The relevance of these response patterns on long-term biventricular remodeling requires further investigation.
- 12 January 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (1) , 80-92
Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Implant in Patients Weighing ≤30 kg
- 12 January 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (1) , 80-92
Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Implant in Patients Weighing ≤30 kg
- Open Access
- 8 December 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (23) , 2949-2951
Adapted Melody Valve Implantation in the Tricuspid Position
- 8 December 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (23) , 2949-2951
Open AccessAdapted Melody Valve Implantation in the Tricuspid Position
- Open Access
- 20 November 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 357-360
Percutaneous Management of Right Ventricular Outflow Tract Obstruction in an Adult Patient After Atrial Switch: A Case for Targeted Infundibular Ablation
Alcohol septal ablation is a well‐established treatment method for patients with hypertrophic cardiomyopathy. We present a case report of a patient with transposition of the great arteries (TGA) after a Mustard procedure, who developed significant right ventricular outflow tract obstruction (RVOTO), functionally resembling subaortic stenosis. Given the high surgical risk, interventional alcohol ablation of the conus branch of the right coronary artery (RCA) was successfully performed, resulting in a significant decrease in the pressure gradient.
- 20 November 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 357-360
Open AccessPercutaneous Management of Right Ventricular Outflow Tract Obstruction in an Adult Patient After Atrial Switch: A Case for Targeted Infundibular Ablation
Alcohol septal ablation is a well‐established treatment method for patients with hypertrophic cardiomyopathy. We present a case report of a patient with transposition of the great arteries (TGA) after a Mustard procedure, who developed significant right ventricular outflow tract obstruction (RVOTO), functionally resembling subaortic stenosis. Given the high surgical risk, interventional alcohol ablation of the conus branch of the right coronary artery (RCA) was successfully performed, resulting in a significant decrease in the pressure gradient.
- Open Access
- 29 October 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 34-37
Intentional Stent Fracture to Accommodate Growth After Coarctation Stenting in an 860‐g Neonate
Background: Congenital aortic coarctation in neonates and children can be managed with transcatheter stent implantation, but this approach raises the issue of how to accommodate the fixed stent structure within the growing vessel. Case Summary: A 15‐month‐old boy, born prematurely with critical aortic coarctation, was treated at 1 week of age with the implantation of a coronary stent. Subsequently, multiple stent dilatations were needed to adapt it to the growing aortic vessel. At 3 months the patient underwent balloon dilation with the simultaneous implantation of a second stent, and after 1 year an ultra‐high‐pressure balloon dilatation with intentional fracture of the coronary stent was performed. Discussion: To overcome the problem of stenting a growing vessel, intentional stent fracture (ISF) with ultrahigh‐pressure (UHP) balloon has been introduced and applied in a limited number of patients. In piglet models, the ISF technique was associated with a significant incidence of complications, which were preventable (with the exception of stent fragment embolization) by performing pre‐stenting before ISF.
- 29 October 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 34-37
Open AccessIntentional Stent Fracture to Accommodate Growth After Coarctation Stenting in an 860‐g Neonate
Background: Congenital aortic coarctation in neonates and children can be managed with transcatheter stent implantation, but this approach raises the issue of how to accommodate the fixed stent structure within the growing vessel. Case Summary: A 15‐month‐old boy, born prematurely with critical aortic coarctation, was treated at 1 week of age with the implantation of a coronary stent. Subsequently, multiple stent dilatations were needed to adapt it to the growing aortic vessel. At 3 months the patient underwent balloon dilation with the simultaneous implantation of a second stent, and after 1 year an ultra‐high‐pressure balloon dilatation with intentional fracture of the coronary stent was performed. Discussion: To overcome the problem of stenting a growing vessel, intentional stent fracture (ISF) with ultrahigh‐pressure (UHP) balloon has been introduced and applied in a limited number of patients. In piglet models, the ISF technique was associated with a significant incidence of complications, which were preventable (with the exception of stent fragment embolization) by performing pre‐stenting before ISF.
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e043468
Off‐Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience
Background: Transcatheter patent ductus arteriosus (PDA) closure can be challenging in cases of large PDA, complex anatomy, and small patient size. We aimed to assess the feasibility, efficacy and safety of the off‐label use of the multifunctional occluder in transcatheter PDA closure. Methods: A retrospective analysis was conducted on patients who underwent transcatheter PDA closure with the multifunctional occluder in 14 pediatric cardiology centers (5 countries) from 2018 to 2025. Results: A total of 77 procedures were performed on 75 patients, including 5 adults (6.7%). Among the 70 children (93.3%; median age: 0.8 years [range, 0.1–10 years], median procedural weight: 6.9 kg [range, 2.1–32.0 kg]), 35 (50.0%) weighed ≤6 kg (median procedural weight: 4.0 kg [range, 2.1–5.9 kg]). The PDA was large, with a minimal ductal diameter of 3.8 mm (range, 1.5–7.0 mm), short in 54.5%, and unrestrictive with increased pulmonary artery pressures in 51.6% of patients. The morphology was predominantly conical (Krichenko type A: 51.9%), with window‐type or complex morphologies representing 26.7% (Type B: 18.2%, Type D: 7.8%). Both arterial and venous femoral accesses were obtained in 87.0% cases, with deployment being antegrade in 77.9% and retrograde in 22.1%. Successful device deployment and release were achieved in 74 cases (96.1%). The rate of major adverse events was 5.2% including 1 early (1.3%) and 3 late complications (3.9%). No other adverse events were reported. Conclusions: The off‐label use of the multifunctional occluder device is a promising option for transcatheter PDA closure, demonstrating safety and efficacy in this series.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e043468
Open AccessOff‐Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience
Background: Transcatheter patent ductus arteriosus (PDA) closure can be challenging in cases of large PDA, complex anatomy, and small patient size. We aimed to assess the feasibility, efficacy and safety of the off‐label use of the multifunctional occluder in transcatheter PDA closure. Methods: A retrospective analysis was conducted on patients who underwent transcatheter PDA closure with the multifunctional occluder in 14 pediatric cardiology centers (5 countries) from 2018 to 2025. Results: A total of 77 procedures were performed on 75 patients, including 5 adults (6.7%). Among the 70 children (93.3%; median age: 0.8 years [range, 0.1–10 years], median procedural weight: 6.9 kg [range, 2.1–32.0 kg]), 35 (50.0%) weighed ≤6 kg (median procedural weight: 4.0 kg [range, 2.1–5.9 kg]). The PDA was large, with a minimal ductal diameter of 3.8 mm (range, 1.5–7.0 mm), short in 54.5%, and unrestrictive with increased pulmonary artery pressures in 51.6% of patients. The morphology was predominantly conical (Krichenko type A: 51.9%), with window‐type or complex morphologies representing 26.7% (Type B: 18.2%, Type D: 7.8%). Both arterial and venous femoral accesses were obtained in 87.0% cases, with deployment being antegrade in 77.9% and retrograde in 22.1%. Successful device deployment and release were achieved in 74 cases (96.1%). The rate of major adverse events was 5.2% including 1 early (1.3%) and 3 late complications (3.9%). No other adverse events were reported. Conclusions: The off‐label use of the multifunctional occluder device is a promising option for transcatheter PDA closure, demonstrating safety and efficacy in this series.
- Open Access
- 21 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7447
Interventions for Fontan Pathway Obstruction in Patients Following Total Cavopulmonary Connection
Background/Objectives: Obstruction of the Fontan pathway is a severe morbidity after total cavopulmonary connection (TCPC). This study aimed to evaluate the incidence and location of TCPC pathway obstruction and corresponding interventions. Methods: In all patients undergoing TCPC between 1994 and 2023, postoperative interventions for TCPC pathway obstruction were evaluated. Risk factors for TCPC pathway interventions were identified, and the impact of TCPC pathway interventions on late outcomes was analyzed. Results: Among 650 patients, 136 (21%) needed catheter/surgical interventions for TCPC pathway obstructions during the median duration of 0.2 (0.03–6.1) years postoperatively. Interventions comprised 128 catheters and 10 surgeries. Catheter intervention included 107 left pulmonary arteries (PA), 8 right PAs, and 27 extracardiac conduits. Surgery included eight conduit revisions, four PA enlargements, and two SVC enlargements. Freedom from interventions at 1, 3, 5, and 10 years was 87.7, 85.3, 83.6, and 78.5%, respectively. Previous Norwood procedure (HR: 2.228, p = 0.003), previous ductal stent (HR: 2.574, p < 0.001), previous PA interventions (HR: 2.514, p < 0.001), and high PA pressure before TCPC (HR: 1.161, p = 0.004) were risk factors. Patients requiring interventions had a higher incidence of protein-losing enteropathy (16.0 vs. 2.0%, p < 0.001), plastic bronchitis (8.3 vs. 0.8%, p < 0.001), and failing Fontan (28.6 vs. 7.6%, p < 0.001), compared to those who did not. Conclusions: Interventions for Fontan pathway obstruction were needed in 21% of patients. The left-PA stenosis was the main lesion, most cases of which were treated by stent implantation. Norwood procedure, ductal stent, pre-TCPC PA intervention, and high pre-TCPC PA pressure were identified as risks factors.
- 21 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7447
Open AccessInterventions for Fontan Pathway Obstruction in Patients Following Total Cavopulmonary Connection
Background/Objectives: Obstruction of the Fontan pathway is a severe morbidity after total cavopulmonary connection (TCPC). This study aimed to evaluate the incidence and location of TCPC pathway obstruction and corresponding interventions. Methods: In all patients undergoing TCPC between 1994 and 2023, postoperative interventions for TCPC pathway obstruction were evaluated. Risk factors for TCPC pathway interventions were identified, and the impact of TCPC pathway interventions on late outcomes was analyzed. Results: Among 650 patients, 136 (21%) needed catheter/surgical interventions for TCPC pathway obstructions during the median duration of 0.2 (0.03–6.1) years postoperatively. Interventions comprised 128 catheters and 10 surgeries. Catheter intervention included 107 left pulmonary arteries (PA), 8 right PAs, and 27 extracardiac conduits. Surgery included eight conduit revisions, four PA enlargements, and two SVC enlargements. Freedom from interventions at 1, 3, 5, and 10 years was 87.7, 85.3, 83.6, and 78.5%, respectively. Previous Norwood procedure (HR: 2.228, p = 0.003), previous ductal stent (HR: 2.574, p < 0.001), previous PA interventions (HR: 2.514, p < 0.001), and high PA pressure before TCPC (HR: 1.161, p = 0.004) were risk factors. Patients requiring interventions had a higher incidence of protein-losing enteropathy (16.0 vs. 2.0%, p < 0.001), plastic bronchitis (8.3 vs. 0.8%, p < 0.001), and failing Fontan (28.6 vs. 7.6%, p < 0.001), compared to those who did not. Conclusions: Interventions for Fontan pathway obstruction were needed in 21% of patients. The left-PA stenosis was the main lesion, most cases of which were treated by stent implantation. Norwood procedure, ductal stent, pre-TCPC PA intervention, and high pre-TCPC PA pressure were identified as risks factors.